This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Medical Product Stocks to Watch From a Challenging Industry
by Indrajit Bandyopadhyay
The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like FHI, NVST, COMM and FLS are seeing price strength and have a high chance of carrying the momentum forward.
Earnings Estimates Moving Higher for Envista (NVST): Time to Buy?
by Zacks Equity Research
Envista (NVST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks.com featured highlights include Kontoor Brands, Envista, Western Digital and LATAM Airlines
by Zacks Equity Research
Kontoor Brands, Envista, Western Digital, and LATAM Airlines make Zacks' GARP screen with low PEG ratios and strong long-term growth potential.
4 GARP Stocks With Solid PEG Scores for Strong Portfolio Gains
by Urmimala Biswas
Four GARP picks with low PEG ratios and strong growth potential include Kontoor Brands, Envista, Western Digital and LATAM Airlines.
Why Envista (NVST) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
NVST vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVST vs. ABT: Which Stock Is the Better Value Option?
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
New Strong Buy Stocks for August 5th
by Zacks Equity Research
ARMN, QUAD, NVST, INDV and BJRI have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2025.
Interpreting Envista (NVST) International Revenue Trends
by Zacks Equity Research
Explore how Envista's (NVST) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Envista (NVST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Envista (NVST) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Envista (NVST) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of +8.33% and +6.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
AdaptHealth (AHCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Envista (NVST) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Envista (NVST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Golden Cross, Envista (NVST)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
Envista (NVST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NVST or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVST vs. ABT: Which Stock Is the Better Value Option?
Elevance Health Q2 Earnings Miss Estimates on Rising Medical Costs
by Zacks Equity Research
ELV's Q2 EPS slides 12.6% y/y and misses estimates as rising Medicaid and ACA costs weigh on the results.
Encompass Health Opens Rehabilitation Hospital in Florida
by Zacks Equity Research
EHC opens its 23rd Florida rehab hospital in Daytona Beach, boosting access to care and supporting its 2025 growth plan.
NVST vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVST vs. ABT: Which Stock Is the Better Value Option?
Should You Add NVST Stock to Your Portfolio Right Now?
by Zacks Equity Research
Envista's global expansion, smart acquisitions, and strong balance sheet support growth but forex risks remain a drag.
All You Need to Know About Envista (NVST) Rating Upgrade to Buy
by Zacks Equity Research
Envista (NVST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. ABT: Which Stock Is the Better Value Option?
Understanding Envista (NVST) Reliance on International Revenue
by Zacks Equity Research
Examine the evolution of Envista's (NVST) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash
by Zacks Equity Research
Envista delivers better-than-expected top and bottom-line results for the first quarter of 2025.